Insertion of a nuclear factor kappa B DNA nuclear-targeting sequence potentiates suicide gene therapy efficacy in lung cancer cell lines

Cancer Gene Therapy

Volumn 19, Issue 10, 2012, Pages 675-683

  Cramer, F ^a   Christensen, C L ^a   Poulsen, T T ^a   Badding, M A ^b   Dean, D A ^b   Poulsen, H S ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

lung cancer; nuclear translocation; suicide gene therapy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; BINDING SITE; CELL MIGRATION; CORRELATION ANALYSIS; CYTOTOXICITY; DNA DETERMINATION; DNA SEQUENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; SUICIDE GENE THERAPY;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; SMALL CELL LUNG CARCINOMA; TRANSFECTION;

EID: 84866373872     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.54     Document Type: Article

References (33)

1. http://www.who.int/mediacentre/factsheets/2012.
2. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011; 378: 1741-1755.
3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 355-367.
4. Lovly CM, Carbone DP. Lung cancer in 2010: one size does not fit all. Nat Rev Clin Oncol 2011; 8: 68-70.
5. Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783-789.
6. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004; 4: 357-372.
7. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008; 29: 3477-3496.
8. Vaughan EE, DeGiulio JV, Dean DA. Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmic movement and nuclear import. Curr Gene Ther 2006; 6: 671-681.
9. Capecchi MR. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980; 22: 479-488.
10. Dean DA, Dean BS, Muller S, Smith LC. Sequence requirements for plasmid nuclear import. Exp Cell Res 1999; 253: 713-722.
11. Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, Sorscher EJ. A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J Pharmacol Exp Ther 2003; 304: 1280-1284.
12. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
13. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ et al. Nuclear factorkappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006; 107: 2637-2646.
14. Miller AM, Dean DA. Tissue-specific and transcription factor-mediated nuclear entry of DNA. Adv Drug Deliv Rev 2009; 61: 603-613.
15. Mesika A, Grigoreva I, Zohar M, Reich Z. A regulated, NFkappaB-assisted import of plasmid DNA into mammalian cell nuclei. Mol Ther 2001; 3: 653-657.
16. Mesika A, Kiss V, Brumfeld V, Ghosh G, Reich Z. Enhanced intracellular mobility and nuclear accumulation of DNA plasmids associated with a karyophilic protein. Hum Gene Ther 2005; 16: 200-208.
17. Goncalves C, Ardourel MY, Decoville M, Breuzard G, Midoux P, Hartmann B et al. An optimized extended DNA kappa B site that enhances plasmid DNA nuclear import and gene expression. J Gene Med 2009; 11: 401-411.
18. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clin Cancer Res 2010; 16: 2308-2319.
19. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-179.
20. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
21. Pedersen N, Mortensen S, Sorensen SB, Pedersen MW, Rieneck K, Bovin LF et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003; 63: 1943-1953.
22. Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS. The insulinomaassociated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther 2006; 13: 375-384.
23. ArenzanaSeisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL et al. Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 1997; 110: 369-378.
24. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
25. Kunsch C, Ruben SM, Rosen CA. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol 1992; 12: 4412-4421.
26. Cohen RN, van der Aa MA, Macaraeg N, Lee AP, Szoka Jr FC . Quantification of plasmid DNA copies in the nucleus after lipoplex and polyplex transfection. J Control Release 2009; 135: 166-174.
27. van Gaal EV, Oosting RS, van Eijk R, Bakowska M, Feyen D, Kok RJ et al. DNA nuclear targeting sequences for non-viral gene delivery. Pharm Res 2011; 28: 1707-1722.
28. Dauty E, Verkman AS. Actin cytoskeleton as the principal determinant of sizedependent DNA mobility in cytoplasm: a new barrier for non-viral gene delivery. J Biol Chem 2005; 280: 7823-7828.
29. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009; 89: 301-314.
30. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 6: 52-62.
31. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-330.
32. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 2006; 281: 14446-14456.
33. Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 2011; 25: 1470-1475.